MUC1-C DEPENDENCY IN DRUG RESISTANT HR+/HER2- BREAST CANCER IDENTIFIES A NEW TARGET FOR TREATMENT WITH AN ANTIBODY-DRUG CONJUGATE

MUC1-C is a common effector of treatment resistant HR+/HER2- BC cells and is a potential target for their treatment Overall design: RNA Seq in HR+/HER2- Cell lines with doxicicline inducible MUC1-C shRNA silencingMUC1-C是治疗抵抗性激素受体阳性（HR+）/人表皮生长因子受体2阴性（HER2-）乳腺癌（Breast Cancer, BC）细胞的常见效应分子，亦是此类细胞治疗的潜在靶点。实验整体设计：对携带多西环素（doxycycline）诱导型MUC1-C短发夹RNA（short hairpin RNA, shRNA）沉默体系的HR+/HER2-乳腺癌细胞系开展RNA测序（RNA Seq）。